Medisun Regenerative Medical Center and Health Summit

Medisun Regenerative Medical Center and Health Summit

Cancer Vaccine | White House Cancer Lunar Plan | Cancer Proton Beam Treatment

ShenZhen- Hong Kong-GuangZhou

The Medisun Medical Health Summit, co-sponsored by Medisun Regenerative Medical Group, New Life Group and Sunshine Medical Group, was held in Shenzhen, Hong Kong and Guangzhou from September 6 to 9, 2017. The theme of this summit is centered around the prevention and treatment of cancer. The authoritative release of cancer vaccine is the strongest focus of this summit.  

Medisun Medical Group has invited a number of authoritative scientists, medical experts, industry leaders, government agency representatives, business leaders and socialites from the United States, Europe, Japan, Hong Kong and Mainland China to collaborate on cancer prevention worldwide. Leading medical health consultations such as therapeutic technologies, industry regulatory development, and medical platform construction have been fully explored. Nearly 5,000 entrepreneur representatives, medical experts and doctors from the Chinese health industry participated in the listening and sharing.

Dozens of media interviews and reports at the summit

Madison Cancer Vaccine Launch Ceremony

Chairman Danny Wong said: “The advent of cancer vaccine is the strongest gospel of cancer prevention!”

According to the World Health Organization (WHO), approximately 14 million new cancer cases are diagnosed each year worldwide, and this number is expected to reach 21 million by 2030. As global treatment costs rise, cancer prevention measures are becoming more and more important, which has also made cancer prevention and treatment a high-profile international issue. Medisun’s comprehensive introduction of cancer vaccines is undoubtedly the strongest gospel for cancer prevention. The WT1 gene is a gene representing tumorigenesis in humans, and all human cancers are associated with this genetic mutation. The Nobel Institute of Ecological Medical Sciences has discovered a pathway to inhibit mutations in the WT1 gene, which can be vaccinated to produce memory T cells that inhibit WT1 gene mutations, which are immune to humans.

In addition, Medisun is also committed to the development and clinical use of a variety of other vaccines. Most of the vaccine technology comes from the United States, investing in rapid response to the pandemic virus and cancer control vaccine technology platform, with a market size of more than 2 billion US dollars. The vaccines invested by Medisun can be modularized in Asia and China to produce vaccines that are fully compliant with the United States. Including: Zika virus, Chikungunya fever, Zika/Chikununya heat combination, Ebola virus, human papillomavirus HPV treatment vaccine, head and neck cancer, cervical cancer, cervical lesions, simple Herpesvirus HSV, hepatitis C virus HCV, hepatitis B virus HBV,etc.

Mr. Danny Wong, Chairman of Medici Medical Group, was interviewed by the media about the release of cancer vaccine.

Chairman Danny Wong specifically said: “China’s rapid economic development over the past 20 years has been accompanied by a wave of globalization. China has integrated into the international community in various fields. At the same time, China has introduced high-standard medical technologies and services from Europe, the United States and Japan. It is our mission to make full use of Hong Kong’s advantages as a mature international metropolis and special geographical factors to provide the world’s most advanced medical care to the people of the motherland.

On-site participants actively asked questions from the cancer vaccine and new cancer treatment technologies to participate in the seminar.

Medisun participates in the White House Cancer Month Plan

Mr. Terry Lierman said: “The greatest progress and breakthrough of mankind is the birth of cancer vaccine!”

Mr. Terry Lierman, a core member of the White House Cancer Month Program, the NIH of the National Institutes of Health, and the founder of the FDA Board of Directors and director of the Meditech Group, said that cancer landing is an amazing cause. It is planned to complete the treatment of 20,000 cancer patients with 60 different technologies worldwide by 2020. This is a task that would have taken at least 10 years to achieve, and we will now achieve it in 5 years. The cancer “moon landing plan” advocated by former US President Barack Obama in 2016 is also the focus of this summit. The plan is led by former Vice President Joe Biden. The goal is to break the boundaries that hinder the cooperation of researchers and accelerate the research of cancer diagnosis and treatment in the future. 5 years to double the progress of anti-cancer research. The six major US cancer “moon landing programs” include cancer vaccines, high-sensitivity cancer early detection, immunotherapy and combination therapy, single-cell genomic analysis of cancer cells and tumor microenvironment cells, new treatments for childhood cancer, and enhanced data. shared. To this end, the United States and Canada, Hong Kong, Germany, Switzerland, Japan, South Korea and other countries, the first-class research units to establish cooperative relations, large-scale joint cancer research and treatment, toward precision Medisun. The Medisun Medical Group is a member of the Cancer Month Program and will also participate in this historic mission.

Mr. Terry Lierman talks about McGrady’s participation in the White House Cancer Month Plan

Medisun introduces Mayo proton beam therapy

Dr. Michael Haddock said: “The Mayo proton beam is a great advancement in the precise treatment of cancer!”

As the Asian Medical Service Center of the Mayo Clinic in the United States, Medisun invited Dr. Michael Haddock, Chairman of the Mayo Radiation Oncology Clinical Practice Committee and Vice Chairman of the American Society of Surgery Oncology (ACOSOG) Committee to talk about radiotherapy for cancer. Dr. Haddock talked about the current Proton Bean, the world’s leading cancer radiotherapy technology, Mayo currently has the most authoritative equipment, operations and medical team for global proton beam therapy. Mayo’s proton beam therapy program is the exclusive feature of pen beam scanning. It can accurately target tumors and prevent healthy tissues from being affected, thus achieving ideal cancer treatment, especially for treating children with cancer. For cancers with high mortality and lung cancer, proton beam therapy has obvious advantages compared with traditional radiotherapy.

At the Hong Kong Summit, Dr. Michael Haddock (left), the authoritative doctor of Mayo cancer proton beam therapy, answered questions from guests at the scene.

Dr. Michael Haddock (left) and Mr. Terry Lierman (right), the authoritative doctors of Mayo cancer proton beam therapy, at the Guangzhou Summit.

Japanese NKT immune cell therapy

Dr. Degang said: “Cancer vaccine and NKT immune cell therapy are the strongest partner in cancer prevention and treatment!”

Haruhiro Tokuoka, CEO of Riken Immunization and Reproductive Medisun, Japan, Dr. Degang Governing, talked about immunotherapy for cancer. Japan has always been a pioneer in cancer immunotherapy and has extensive clinical experience. Japan Riken and Medisun have worked closely together and established the Medisun Precision Medical Joint Venture, which applies NKT immunocytotherapy outside the traditional cancer treatment to clinical treatment of various types of cancer in the early, middle and late stages, and has clinically proven to greatly improve cancer patients. High quality of immunotherapy at the same time as quality of life with almost no side effects.

Dr. Kazuoka Kazuo of Japan at the Hong Kong Summit to explain the effectiveness of NKT immune cell therapy in clinical treatment of cancer.  

Dean He Jianxing (second from right) of Guangzhou Medical First Hospital visited the Guangzhou Summit and participated in Dr. Degang Zhiwei (third from left) on cell immunotherapy

Precision Medisun and anti-cancer cancer

Ms. Yanglan said: “As a mother, I chose to give my daughter a HPV cervical cancer vaccine; now the launch of the cancer vaccine is even more exciting!”

In today’s society, everyone is tired of work, and it is often the easiest to ignore their good habits, which leads to the emergence of various diseases . In fact, “health is the first wealth of life”, Emerson’s famous interpretation perfectly interpreted the importance of a healthy life to people. Ms. Yang Lan, a well-known Chinese media person, attended the summit as a guest and shared ideas about health and happiness with the guests. She said that the pain caused by cancer patients to the family cannot be expressed in words, and health is good for every family. Precious, we need to follow the development of science and technology to update our medical knowledge. Nowadays, precision Medisun has brought us new choices. While we are not blindly following, we should fully understand the physical condition of ourselves and our families, and choose the right medical health program for ourselves.

Ms. Yang Yu shared about cancer treatment.  

Ms. Wu Shuqing, the Honorary Director of the World Trade Center Association and the Standing Committee of the National Committee of the Chinese People’s Political Consultative Conference, was unable to visit the summit due to the temporary overseas meeting. She also sent a congratulatory message to the summit and congratulated Chairman Danny Wong of the Medisun Medical Group: “The summit has deepened Hong Kong with the Chinese mainland again, we are highly concerned about the medical and health industry. Therefore, I believe that Medisun Medical Group will continue its leading position in the field of medical and health care. Since the beginning, I have seen the entire team of Medisun under the leadership of Chairman Danny Wong. Unremitting efforts and dedication, I am convinced that today’s event is only the beginning, I hope that more results will be shared with the whole society.”

As a pioneer in the field of stem cells, cancer prevention and treatment in the world of regenerative , Medisun Medical Group has been committed to introducing the world’s leading cancer prevention and treatment technologies and providing the most advanced, professional and excellent medical and health services to the society. The release of the cancer vaccine is a revolutionary advancement in the field of cancer prevention. Ancient smallpox is terminally ill, and now a single shot of smallpox disappears; in the past, hepatitis B was terminally ill, and now a vaccine is immunized for life; yesterday, cancer is terminally ill, and today’s cancer vaccine keeps cancer away. Time is advancing and science is progressing. We must have a mentality of accepting progress. We believe that cancer prevention can provide shelter for the family and the health and well-being of  society.

Stay tuned: Hong Kong’s latest publication “CAPITAL” magazine in September, cover story “Mr. Danny Wong, Chairman of Medisun Medical Group” and cover story “New Revolution in Medical Industry”.

You can contact the Hong Kong Medisun Regenerative Medical Center to receive a magazine. Contact as below:

Phone: +(852) 2582 0188

Email: info@medisun.hk

WeChat: medisuninfo

Website: www.medisun.hk

****************************************

Medisun Medical Group

Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative  products, as well as top hospitals and treatment centers. Located on the 25th floor of Ao Teng Plaza, Kowloon Bay, Hong Kong, the Medisun Reproductive Centre has a 50,000-square-foot stem cell GMP production facility, a cancer treatment centre and an anti-aging centre. It brings together European, Japanese, American and individual Chinese experts to be rigorous and professional. The development process provides immune cell therapy and a variety of stem cell health treatments. As the Asian service organization of Mayo Clinic, the center provides Mayo remote consultation and secondary treatment to enable Chinese patients to enjoy authoritative medical services without leaving the country. More than 3,000 biomedical tests provide the most predictable health protection for the health of our clients. Medisun has been fully supporting the development of the new life and health platform, and is committed to the deepening of the new products and technologies of regenerative Medisun through this platform, truly benefiting the health of the whole society.

For more details, please visit http://www.medisun.hk/

ANEXIO Named One of the 10 Best Security Companies

ANEXIO, the leading “Desktop to Data Center” infrastructure-as-a-service company, today announced that is has been named one of the 10 best security companies in 2017 by CIO Bulletin. This recognition is due, in part, to ANEXIO’s ability to help customers securely accelerate their digital transformation by implementing a multilayered security architecture, driven by industry compliance standards, across the company’s managed services platform.

ANEXIO specializes in helping customers transition from their legacy IT environment to a more secure digital infrastructure. Companies transforming into digital enterprises typically share three characteristics:

1. Applications have become the revenue driver of their business

2. Users expect flawless experience from those applications

3. The security for these mission critical applications has become more complex

“Every day, more and more mid-market companies are becoming full-time digital enterprises,” said Tony Pompliano, ANEXIO President and CEO. “It’s an honor to receive this recognition from CIO Bulletin, but, even more importantly, it’s an honor to help our customers accelerate their digital transformation. ANEXIO is proud of the technology investments that we’ve made to help secure the experience of our digital end users against the ever-increasing security threats that all enterprises face in today’s connected world of applications, networks, data centers and hybrid clouds.”

ANEXIO understands that no two customer digital transformations are alike. Physical, logical and virtual security is woven into the fabric of ANEXIO’s offerings. The company’s phased migration process addresses the unique challenges of each customer:

1. Assessment Phase: Clarify the customer’s business objectives, understand the operational risks and then identify the migration path to the ANEXIO Cloud.

2. Decision Phase: ANEXIO experts create a comprehensive, end-to-end transition plan with special focus on security, performance, and zero downtime for the customer.

3. Implementation Phase: ANEXIO engineers work with the customer to finalize the migration schedule, provision the environment and then commence the migration to the ANEXIO cloud.

Customers interested in learning more about ANEXIO’s security portfolio or digital transformation capabilities can email info@anexio.com and request a briefing.

ABOUT ANEXIO

ANEXIO is transforming the IT industry with Desktop to Data Center solutions designed specifically for customers seeking a smooth transition from legacy IT environments to a more efficient Hybrid Cloud infrastructure. The Inc. 500 company’s Mission Critical Infrastructure strategy is anchored by eight Tier III SOC-2 certified data centers, an IT solutions center and a nationwide IP Network. ANEXIO’s offerings include colocation, networking, Cloud services, storage, disaster recovery, Managed IT and Managed VoIP. Every ANEXIO product and service is backed up by United States-based customer support. Visit www.anexio.com for more information.

Media Contact:

Amy Laukka
(919) 802-4304
alaukka@boltpr.com

SOURCE ANEXIO
Related Links

Home

The famous american virologist Robert Gallo joined Medisun Medical Group

The famous American virologist – HIV virus discoverer Robert Gallo joined Medisun Medical Groupedisun

Bringing the best cancer and AIDS treatment technologies to China

Robert Gallo, a famous American virologist, joined Medisun Medical Groupedisun

In February 2017, Medisun Medical Group officially announced the appointment of Robert Charles Gallo, a famous American virologist, as a member of the board of directors of the group.

https://pbs.twimg.com/profile_images/461587078824738817/w8khfwWL.jpeg 

Dr. Robert Charles Gallo

Dr. Gallo is a famous American virologist whose best-known contribution is the discovery of the first human retrovirus (HTLV1, and HTLV2). In 1983, HTLV3 was discovered, which was later called the HIV, a virus that causes AIDS. He also studied the cytokine leukocyte 2, and in 1986 studied the pathogen human rash type 6 virus in children with acute rash. In 1982 and 1984, he received the Lasker Basic Medical Research Award (known as the “Nobel Prize in the United States”), the Charles Mott Award (Tumor Prevention Contribution Award) in 1984, and the Dickson International Award in 1985, 1988. Received the National Science and Technology Outstanding Contribution Award from Japan. Dr. Gallo is currently the Director of the Institute of Human Virology (IHV) at the University of Maryland and the founder and chief scientist of the Global Virus Network (GVN). He has served in the National Cancer of the United States. The National Cancer Institute has served as the director of the Laboratory of Cancer Cell Biology for 30 years. Dr. Gallo proposed the theory that the tumor system is caused by viruses and gradually improved its academic structure and clinical research.

Mr. Terry L. Lierman, founder of the US FDA, joined Medisun

At the same time , Mr.Terry L. Lierman entered the board of Medisun. Mr. Lierman is the founder of Summit Global Ventures and the CEO of Health Ventures LLC.Mr. Lierman has served on the US Senate Appropriations Committee and served as Director of the Sub-Committee on Labor Health and Human Services (HHS) Grants. Mr. Lierman is also the founder of Research America and NIH (National Institutes of Health) / FDA (US Food and Drug Administration) Board of Directors, and serves as the majority leader and member of the House of Representatives. He began his career in the health field of the NIH (National Institutes of Health) in 1971, where he assisted with budget and policy development, grants and contracts. For the past four decades, he has combined entrepreneurs and political talent in a variety of businesses.From leadership positions in the US Senate Appropriations Committee, founding companies and non-profit organizations, to promote health care advocacy, to lead and serve as chairman of the Maryland Democratic Party.

Mr.Terry L.Lierman

Chairman Medisun Wang Xiaofeng joined the Board of Directors of the Institute of Human Virology and the International Virus Alliance

At the same time that two world-class companies joined Medisun, Mr. Wang Xiaofeng, Chairman of Medisun Medical Group, was also invited to the Institute of Human Virology (IHV) and the Global Virus Network (GVN) at the University of Maryland as a member of the board of directors. Mr. Wang is the founder and chairman of the Board of Directors of Medisun Medical Group living in Canada and the United States for ten years. He moved to Hong Kong in 1996. Mr. Wang has more than 20 years of experience in the global capital market and medical industry, including industries including Medisunne, internet, education and media. Mr. Wang is currently Chairman of Hong Kong-listed National Investment Fund (01227.HK) and Chairman of Beijing Financial Group.

Mr. Danny Wong

Headquartered in Hong Kong, Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative Medisunne products, as well as top hospitals and treatment centers.

Medisun invests extensively in the fields of regenerative Medisunne and stem cell patent technology, including stem cell therapy for heart failure, stem cell therapy for liver disease, kidney disease, nervous system disease, cancer, AIDS, and immune cell therapy for a variety of cancers. Medisun Medical has a long-term cooperation plan with the US-Australia Clinic, the Harvard University Stem Cell Institute, and the Johns Hopkins Medical School Life Science Center to jointly invest in regenerative Medisunne and stem cell therapy technology, with Medisun as a co-operative business. The Medisun holding entity and holds global intellectual property rights.

The Medisun Reproductive Medisunne Centre is located at the Proud Square in Kowloon Bay, Hong Kong. It has a 50,000 square foot stem cell GMP production base, a cancer treatment centre and an anti-aging centre. It brings together European, Japanese, American and individual Chinese experts to develop a rigorous and professional R&D process. Provides immune cell therapy and a variety of stem cell health treatments. As the Asian service organization of Mayo Clinic, the center provides Mayo remote consultation and secondary treatment to enable Chinese patients to enjoy authoritative medical services without leaving the country. 3,300 biomedical tests provide the most predictable health protection for customers’ health, adding more than 300 new testing items each year.

MEDISUN REGENERATIVE MEDICAL CENTER | CANCER TREATMENT CENTER | ANTI-AGING CENTER

Medisun Medical Laboratory (Hong Kong)

Medisun Medical Laboratory (Hong Kong)

Medisun announced that he will join the Biden Cancer Lunar Plan

At the end of 2016, Medisun announced that he would join the “Cancer Moon Plan” initiated by former US Vice President Biden. The “Cancer Moon Plan” was proposed by former US President Obama in early 2016 and was initiated by former Vice President Biden. The goal is to shorten the work schedule for cancer-related prevention, diagnosis, treatment and care that was expected to be completed in 5 years. Aiming to achieve 20,000 cancer treatments worldwide by 60 programs by 2020.
Dr. Gallo and Mr. Lierman will lead Medisun’s clinical research implementation, medical technology and project selection, medical resource introduction, etc., and bring the best technology in the world to China, highlighting the inevitable trend of China’s participation in the world’s most advanced technology research and development. . At the same time, Medisun’s clinical research bases in Hong Kong, Beijing, Shanghai, Guangzhou and Tokyo will participate in the world’s most advanced clinical research.
Dr. Gallo and Mr. Lierman joined Medisun and Chairman Wang Xiaofeng to enter the IHV and GVN Board of Directors, indicating that Medisun will work with IHV and GVN to make valuable preparations for the cancer landing program and to fully participate in the global research and development of cancer treatment.

The Human Virology Institute (IHV) is the world’s first research center that combines basic science, epidemiology and clinical research disciplines to accelerate the diagnosis and treatment of chronic viruses and immune diseases (mostly HIV, AIDS the reason). IHV’s laboratory is a US key laboratory that receives more than $200 million in annual US research funding.
Founded in 1996 as a partner of the University of Maryland, IHV is a research institute at the University of Maryland School of Medisun, bringing together a globally recognized and world-renowned expert in human virology. The IHV was co-founded by Robert Gallo (Director of IHV) and William Blattner.MD. The IHV also includes the Animal Model Department, the Basic Science Department and the Vaccine Research Department.
The institute has a variety of laboratory and patient care facilities located in Baltimore, Maryland. IHV has created an environment of close collaboration between multidisciplinary research, education and clinical research and development, accelerating scientific understanding of the incidence of HIV/AIDS, and developing interventions to curing cancers of HIV and viruses possible.
IHV’s research focuses on how to use the body’s natural chemistry to its own therapeutic potential, and to discover biotherapeutics that are less toxic to the body and more economical for the public. IHV is also committed to developing effective therapeutic and preventive vaccines that are dedicated to ending the AIDS epidemic.
IHV has more than 300 employees, including 70 professors, whose research focuses on chronic human viral infections and diseases. Currently, more than 75% of the Institute’s clinical and research work addresses HIV infection, but also includes hepatitis C virus, human T-cell leukemia virus 1 and 2, human papillomavirus, herpes virus and cancer research. The patient base of IHV has grown from just 200 patients to about 6,000 in Baltimore, and nearly 1 million in 6 African and 1 Caribbean countries.

The Global Network of Viruses (GVN) is a global organization for the research of viral diseases. It is a consortium of authoritative virologists from more than 20 countries around the world. It is dedicated to the research, development of drugs and vaccines to prevent diseases and death. GVN is the only single organization in the world that has special research in all areas of the virus. GVN brings together the world’s best medical virology experts to focus on difficult scientific issues around the world. The strength of GVN lies in its global reach, the depth of science, and its vision to address the viral challenges facing humanity.

GVN achieves its goals through three strategic action platforms:

Support research

Public education

Advocate a statement supporting the global virus network

Established in Washington, DC, the organization supports the goals and ideals of a global virus network, actively trains younger generations of medical virologists, and provides advice to governments or NGOs on viral diseases to fill the current international health development important needs.

Source: http://www.medisun.hk/

Hong Kong National Investment and Harvard University Stem Cell Institute starting a high quality cooperation

Hong Kong National Investment and Harvard University Stem Cell Institute have a strong cooperation.

Mr. Brock Reeve, CEO of Harvard Stem Cell Research Institute, is the Chief Investment Officer of Stem Cell and Regenerative Medisun at National Investment and Medici Medical Group.

2015-05-11 China Securities Journal

On May 8, 2015, Hong Kong Medisun Regerative Medical Center and National Investment (01227.HK) announced the appointment of Mr. Brock Reeve as the chief stem cell and regenerative medicine investment officer of the two companies.

Mr. Brock Reeve is currently the Executive Director of the Harvard University Stem Cell Institute and has graduated from Yale University and Harvard Business School. Mr. Reeve is solely responsible for the strategy and operations of the Harvard Stem Cell Institute, whose overall goal is to use stem cell biology as a tool and treatment to study and treat major degenerative diseases.

As the Chief Investor of Stem Cell and Regenerative Medicine of Medisun Medical Center, Mr. Brock Reeve will organize and lead a professional investment team to actively select the latest regenerative medicine technologies in overseas markets such as Europe, the United States, and Japan and evaluate their investment value. They will also focus on and invest in the world’s leading stem cell regenerative medicine technology, and actively participate in clinical trials and product commercialization of stem cell technology invested by Medisun Medical Center in Asia.

Medisun Medical Center is the world’s most authoritative investment organization in stem cell and regenerative medicine

As the world’s most authoritative investment organization for stem cells and regenerative medicine, Medisun Medical Center has invested in stem cell treatment technologies including heart, tumor, liver, kidney, AIDS and other diseases, fully demonstrating its investment vision and courage. After working with the Mayo Medical Group in the United States, the Medisun once again joined forces with the Harvard University Stem Cell Institute.

Mr. Danny Wong is both the Chairman of the Medisun Medical Group and National Investment (01227.HK). He has devoted himself to research and investment in the field of stem cells for the past five years. The Medisun currently has more than 300 scientists , medical consultants and investment experts from all over the world. The technologies invested by the group are distributed in Europe, the United States, Japan, Hong Kong and other places, and clinical trials are carried out simultaneously.

China’s first participation in international multi-center global synchronized clinical trials

Medisun Medical Group is committed to bringing the world’s leading stem cell and regenerative medicine technologies to China. The investment in the C-cure stem cell therapy for ischemic heart failure technology, which was invented by Mayo Medical Group, has been clinically tested in Europe and the United States. It will carry out clinical trials in China’s well-known cardiovascular hospitals such as Beijing Anzhen Hospital, Fuwai Cardiovascular Hospital and Shanghai Oriental Hospital with the support of international multi-center policy, giving Chinese hospitals the opportunity to participate in the world’s most advanced stem cell technology clinic. The Medisun also actively promote the commercialization of technology worldwide in the future. Before C-Cure’s great technology and revolutionary products for heart disease were officially launched, Medisun has launched a series of cell regeneration factor products to treat a number of diseases, and the product has entered the market.

Liang Zhen ying visits Harvard University Stem Cell Research Institute and Mr. Brock Reeve to discuss the promotion of stem cell and the development of regenerative medicine industry

Under the general environment of Hong Kong’s adjustment of the whole industry, one of the important measures is to develop the stem cell and regenerative medicine industries. Looking at the huge investment in the stem cell and regeneration field of the Medisun Medical Group, it is revealed that it will inevitably set off a disruptive business model in the market.

The Hong Kong government attaches great importance to the development of stem cells. Following the cooperation with the Caroline Medical School in Sweden, Liang Zhen ying visited the Harvard University Stem Cell Research Institute on May 5 and exchanged views with its Executive Director Brock Reeve to promote the development of the stem cell industry in Hong Kong. This will undoubtedly inject a strong shot into the cooperation between Harvard University and Hong Kong in the field of regenerative medicine. It will promote the promotion of Harvard stem cells in regenerative medicine research and technology in Hong Kong and Asia.

It can be seen that Medisun Medical Group has appointed Mr. Brock Reeve take the helm of the stem cell and regenerative medicine to investment. National Investment (01227.HK), which holds a 30% stake in Medisun Medical Group, is investing in regenerative medicine and the field of stem cells. Mr. Brock Reeve will lead the Medisun Medical Group to become a professional stem cell investment team with global leadership.

The value of the stem cell and regenerative medicine industry under the capital market in China and Hong Kong is immeasurable.

With the upcoming clinical management of stem cells, the development of China’s stem cell and regenerative medicine industry will be unstoppable. Shanghai-Hong Kong Stock Connect and the upcoming Shenzhen-Hong Kong Stock Connect have apparently injected huge sums of money into Hong Kong stocks. The stocks of companies related to the stem cell industry have risen very well, but they are far from satisfactory and far from the technology held by Medisun Medical Center. National Investment (01227.HK), as a shareholder of Medisun Medical Group, is full of confidence in the development of the Group.

Medisun Investment Holdings’ Cardio Biotech plans to enter the US capital market.

Medisun Investment Holdings’ C-cure Stem Cell Therapy for Ischemic Heart Failure has exceeded the number of patients enrolled by the European Food and Drug Administration (EMA) in the Phase III clinical trial in Europe and has been approved by the US Food and Drug Administration (FDA). Enter the third phase of clinical. Cardio, the investment holding company of Medisun, also successfully obtained a new round of financing of 32 million euros in February this year. Its financing quota was oversubscribed and snapped up by European and American institutional investors. Cardio is planning to be listed on the NASDAQ in the United States from the end of May to the beginning of June this year (listed in Belgium and France in 2013), and the large-scale financing plan of Cardio further indicates that the spring of stem cells has really come.

After many years of favor and investment in the field of stem cells and regenerative medicine, and the huge capital investment plan, the Medisun’ next step will be the focus of the market. The capital market’s confidence in its shareholder, National Investment (01227.HK), is already evident in the expectation of its future development.According to analysts, Medisun has planned to launch an overall listing financing plan in Hong Kong in the near future. We believe that Medisun, as a recognized leader in the global stem cell and regenerative medicine field, will surely launch an incredible wave of development in this field.

The News Picture:

P1:

Mr. Brock Reeve is both the chairman of Medisun medical group and National Investment (01227.HK) and a close friend of Mr. Danny Wong during his stay in the United States.They share the same confidence and enthusiasm for stem cell and regenerative medicine.

P2:

Hong Kong Chief Executive Liang Zhen ying visited the Harvard University Stem Cell Institute and exchanged views with the Executive Director, Mr. Brock Reeve, on the development of the stem cell and regenerative medicine industries.

Source: http://www.medisun.hk/

Brock Reeve is the younger brother of the famous American actor Christopher Reeve. Christopher Reeve (September 25, 1952 – October 10, 2004), a New Yorker, famous movie actor, film director, writer, was play in Superman (Kal-El/Clark Kent). He graduated from Cornell University in 1974 with a Bachelor of Arts degree and then entered the Juilliard School in New York. He is also a good friend with another famous actor Robin Williams. In 1978, he starred in the sci-fi film “Superman” for the first time and became a hit. In 1995, an accident occurred during an equestrian competition. The spine was seriously injured and his body was paralyzed. Since then, he has devoted himself to social welfare undertakings and to promote stem cell research. He often holds tour lectures. On October 9, 2004, he died for the myocardial infarction at the age of 52.